GlassScriptPhysician profile
Aaron W Bowman
NPI 1760472344
$5,983.71
in general payments reported to CMS, 2019-2025
27 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $347 · 2021: $670 · 2022: $626 · 2023: $1,079 · 2024: $1,327 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,637 · Entertainment: $64.03 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,637.16 |
| Entertainment | $64.03 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $717.96 | 2019-2025 | Total30, Precision7, Tryptyr |
| Lumenis Be INC | $582.87 | 2025 | Optilight |
| Biotissue Holdings INC. | $570.82 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $454.87 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $443.30 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $434.14 | 2019-2020 | |
| Oyster Point Pharma, INC. | $410.77 | 2022-2024 | Tyrvaya |
| Topcon Healthcare, INC. | $407.91 | 2021-2023 | |
| Coopervision INC. | $345.34 | 2020-2024 | Myday Contact Lens, Misight Contact Lens |
| Bausch & Lomb Americas INC. | $296.14 | 2022-2025 | Miebo, Xiidra, Infuse |
| Optos, INC. | $191.29 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $180.30 | 2019-2023 | |
| Abbvie INC. | $151.08 | 2022-2025 | Alphagan P, Lumigan |
| Kala Pharmaceuticals, INC. | $149.86 | 2020-2022 | |
| Lombart Brothers, INC. | $139.49 | 2019-2025 | Opd-III |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abb Con-Cise Optical Group LLC | $127.32 | 2020-2022 | |
| Allergan, INC. | $109.17 | 2020-2022 | |
| Alcon Research LLC | $54.56 | 2019 | |
| Harrow Eye, LLC | $49.88 | 2024-2025 | Vevye |
| Astellas Pharma US INC | $40.74 | 2024 | Izervay |
| Johnson & Johnson Vision Care, INC. | $28.55 | 2024 | |
| Thea Pharma INC. | $20.94 | 2025 | Iyuzeh |
| Dompe US, INC. | $19.34 | 2022 | |
| Shire North American Group INC | $17.33 | 2019 | |
| Maculogix, INC. | $14.28 | 2020 | |
| Lkc Technologies, INC. | $12.90 | 2025 | |
| Carl Zeiss Meditec, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bowman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.